{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 443919033
| IUPAC_name = 2-(furan-2-ylmethylsulfinyl)-''N''-[(''Z'')-4-[4-(piperidin-1-ylmethyl)pyridin-2-yl]oxybut-2-enyl]acetamide
| image = Lafutidine.svg
| width = 300

<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|international|lafutidine}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status =  
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 118288-08-7
| ATC_prefix = A02
| ATC_suffix = BA08
| ATC_supplemental =  
| PubChem = 5282136
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 49S4O7ADLC
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D01131
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 4445337

<!--Chemical data-->
| chemical_formula =  
| C=22 | H=29 | N=3 | O=4 | S=1 
| molecular_weight = 431.54 g/mol
| smiles = C1CCCCN1Cc2ccnc(c2)OC/C=C\CNC(=O)CS(=O)Cc3ccco3
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C22H29N3O4S/c26-21(18-30(27)17-20-7-6-14-28-20)23-9-2-5-13-29-22-15-19(8-10-24-22)16-25-11-3-1-4-12-25/h2,5-8,10,14-15H,1,3-4,9,11-13,16-18H2,(H,23,26)/b5-2-
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = KMZQAVXSMUKBPD-DJWKRKHSSA-N
}}

'''Lafutidine''' ([[International Nonproprietary Name|INN]]) is a second generation [[H2 antagonists|histamine H<sub>2</sub> receptor antagonist]] having multimodal mechanism of action and used to treat [[gastrointestinal disorders]].  It is marketed in Japan and India.

==Medical use==
Lafutidine is used to treat [[gastric ulcers]], [[duodenal ulcers]], as well as wounds in the lining of the stomach associated with acute [[gastritis]] and acute exacerbation of chronic gastritis.<ref name=StogarLabel/><ref name=LafaxidLabel/>

==Adverse effects==
Adverse events observed during clinical trials included [[constipation]], [[diarrhea]], drug [[rash]], [[nausea]], [[vomiting]] and [[dizziness]].<ref name=LafaxidLabel/>

== Mechanism of action==
Like other [[H2 antagonist|H<sub>2</sub> receptor antagonists]] it prevents the secretion of [[gastric acid]].<ref name=LafaxidLabel/> It also activates [[calcitonin gene-related peptide]], resulting in the stimulation of [[Biological functions of nitric oxide|nitric oxide]] (NO) and regulation of gastric mucosal blood flow, increases [[somatostatin]] levels also resulting in less gastric acid secretion, causes the stomach lining to generate more [[mucin]], inhibits [[neutrophil]] activation thus preventing injury from [[inflammation]], and blocks the attachment of ''[[Helicobacter pylori]]'' to gastric cells.<ref name=LafaxidLabel/>

==Trade names==
It is marketed in Japan as '''Stogar''' by [[UCB (company)|UCB]]<ref name=StogarLabel>UCB Japan Revised: April 2005 [http://www.ucb.com/_up/ucb_com_products/documents/STOGAR-April2005(050414)_tcm62-3741_tcm81-8593.pdf Stogar tablets]</ref> and in India as '''Lafaxid''' by Zuventus Healthcare.<ref name=LafaxidLabel>Zuventus Healthcare Ltd. India [http://www.zuventus.co.in/doctor_wise_products_selected.aspx?Medi_Id=39 Lafaxid tablets]</ref>

==References==
{{reflist}}

{{H2-receptor antagonist}}
{{Histaminergics}}

[[Category:Acetamides]]
[[Category:Alkene derivatives]]
[[Category:Furans]]
[[Category:H2 receptor antagonists]]
[[Category:Phenol ethers]]
[[Category:Piperidines]]
[[Category:Pyridines]]